Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more
Takeda Pharmaceutical Co. Ltd. (TKPHF) - Total Assets
Latest total assets as of December 2025: $15.42 Trillion USD
Based on the latest financial reports, Takeda Pharmaceutical Co. Ltd. (TKPHF) holds total assets worth $15.42 Trillion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Takeda Pharmaceutical Co. Ltd. - Total Assets Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Takeda Pharmaceutical Co. Ltd. - Asset Composition Analysis
Current Asset Composition (March 2025)
Takeda Pharmaceutical Co. Ltd.'s total assets of $15.42 Trillion consist of 17.7% current assets and 82.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.7% |
| Accounts Receivable | $725.25 Billion | 5.1% |
| Inventory | $1.22 Trillion | 8.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.63 Trillion | 25.5% |
| Goodwill | $5.32 Trillion | 37.4% |
Asset Composition Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Takeda Pharmaceutical Co. Ltd.'s current assets represent 17.7% of total assets in 2025, a decrease from 65.2% in 2001.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, down from 36.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 17.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 37.4% of total assets.
Takeda Pharmaceutical Co. Ltd. Competitors by Total Assets
Key competitors of Takeda Pharmaceutical Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Takeda Pharmaceutical Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Takeda Pharmaceutical Co. Ltd. generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Takeda Pharmaceutical Co. Ltd. generates $ 0.76 in net profit.
Takeda Pharmaceutical Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.31 | 1.45 |
| Quick Ratio | 0.65 | 0.72 | 0.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $506.70 Billion | $ 656.32 Billion | $ 769.68 Billion |
Takeda Pharmaceutical Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Takeda Pharmaceutical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | $14.25 Trillion |
| Market Capitalization | $47.47 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Takeda Pharmaceutical Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Takeda Pharmaceutical Co. Ltd.'s assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Takeda Pharmaceutical Co. Ltd. (2001–2025)
The table below shows the annual total assets of Takeda Pharmaceutical Co. Ltd. from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $14.25 Trillion | -5.70% |
| 2024-03-31 | $15.11 Trillion | +8.25% |
| 2023-03-31 | $13.96 Trillion | +5.92% |
| 2022-03-31 | $13.18 Trillion | +2.06% |
| 2021-03-31 | $12.91 Trillion | +0.71% |
| 2020-03-31 | $12.82 Trillion | -7.58% |
| 2019-03-31 | $13.87 Trillion | +237.82% |
| 2018-03-31 | $4.11 Trillion | -5.72% |
| 2017-03-31 | $4.36 Trillion | +13.90% |
| 2016-03-31 | $3.82 Trillion | -10.99% |
| 2015-03-31 | $4.30 Trillion | -5.97% |
| 2014-03-31 | $4.57 Trillion | +15.51% |
| 2013-03-31 | $3.96 Trillion | +10.58% |
| 2012-03-31 | $3.58 Trillion | +28.37% |
| 2011-03-31 | $2.79 Trillion | -1.31% |
| 2010-03-31 | $2.82 Trillion | +2.29% |
| 2009-03-31 | $2.76 Trillion | -3.13% |
| 2008-03-31 | $2.85 Trillion | -7.27% |
| 2007-03-31 | $3.07 Trillion | +0.99% |
| 2006-03-31 | $3.04 Trillion | +19.52% |
| 2005-03-31 | $2.55 Trillion | +8.98% |
| 2004-03-31 | $2.34 Trillion | +13.42% |
| 2003-03-31 | $2.06 Trillion | +4.79% |
| 2002-03-31 | $1.97 Trillion | +12.44% |
| 2001-03-31 | $1.75 Trillion | -- |